Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jon P Gockerman

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemiaDavid A Rizzieri, Valerie K Ibom, Joseph O Moore, et al.
Leukemia & Lymphoma|August 11, 2011
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemiaMark C Lanasa, Patricia H Davis, Michael Datto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2009
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemiaDaphne R Friedman, J Brice Weinberg, William T Barry, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 8, 2009
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myelomaCristina Gasparetto, Jon P Gockerman, Louis F Diehl, et al.
Cancer Chemotherapy and Pharmacology|November 17, 2010
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)Karen E Bullock, William P Petros, Islam Younis, et al.
Blood|April 22, 2004
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphomaDavid A Rizzieri, Gamal Akabani, Michael R Zalutsky, et al.
American Journal of Hematology|July 27, 2007
Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemiaJ Brice Weinberg, Alicia D Volkheimer, Youwei Chen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 13, 2009
Occult primary cancer clinical practice guidelinesDavid S Ettinger, Juan P Arnoletti, Jon P Gockerman, et al.
Blood|August 17, 2011
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment targetDale J Christensen, Youwei Chen, Jessica Oddo, et al.
Cancer Investigation|June 5, 2010
Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapyChristopher A Crout, Liang-Piu Koh, Jon P Gockerman, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemiaDavid A Rizzieri, Valerie K Ibom, Joseph O Moore, et al.
Leukemia & Lymphoma|August 11, 2011
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemiaMark C Lanasa, Patricia H Davis, Michael Datto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2009
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemiaDaphne R Friedman, J Brice Weinberg, William T Barry, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 8, 2009
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myelomaCristina Gasparetto, Jon P Gockerman, Louis F Diehl, et al.
Cancer Chemotherapy and Pharmacology|November 17, 2010
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)Karen E Bullock, William P Petros, Islam Younis, et al.
Blood|April 22, 2004
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphomaDavid A Rizzieri, Gamal Akabani, Michael R Zalutsky, et al.
American Journal of Hematology|July 27, 2007
Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemiaJ Brice Weinberg, Alicia D Volkheimer, Youwei Chen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 13, 2009
Occult primary cancer clinical practice guidelinesDavid S Ettinger, Juan P Arnoletti, Jon P Gockerman, et al.
Blood|August 17, 2011
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment targetDale J Christensen, Youwei Chen, Jessica Oddo, et al.
Cancer Investigation|June 5, 2010
Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapyChristopher A Crout, Liang-Piu Koh, Jon P Gockerman, et al.
Pageof 6